Multiple myeloma · 22 regimens
Cost vs Efficacy · 9 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KTD Variant #01 | — | R 156 174 | 28d | — | — | — | — | — |
Thalidomide and Dexamethasone (TD) Variant #12 | — | R 57 486 | 29d | ~18.6 mo | ~63.2 mo | ~20 | ~R 1 149 724 PFS proxy · indirect | 3 |
Melphalan monotherapy, then Busulfan and Fludarabine, then allo HSCT Variant #01 | — | R 56 106 | — | — | — | — | — | — |
VTD Variant #10 | — | R 46 769 | 42d | ~35.8 mo | — | ~26 | ~R 1 215 998 PFS proxy · indirect | 1 |
Thalidomide and Prednisolone (TP) Variant #01 | — | R 29 231 | 28d | — | — | — | — | 1 |
VMP Variant #05 | — | R 13 012 | 42d | ~17.3 mo | ~56.4 mo | ~13 | ~R 169 162 PFS proxy · indirect | 8 |
RVD Variant #01 | — | R 10 486 | 28d | 46.2 mo | — | 51 | R 534 771 PFS proxy | 3 |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | 33.6 mo | — | 30 | R 256 183 PFS proxy | 3 |
MPR N/A - secondary systemic drug | — | R 6 340 | 28d | 22.4 mo | — | 25 | R 158 501 PFS proxy | 2 |
Melphalan monotherapy, then Melphalan and Busulfan Variant #01 | — | R 5 661 | — | — | — | — | — | — |
Bortezomib and Melphalan Variant #01 | — | R 3 617 | — | — | — | — | — | — |
Melphalan and Methylprednisolone Variant #01 | — | R 3 219 | — | — | 54.1 mo | — | — | — |
DCEP Variant #01 | — | R 1 586 | 28d | — | — | — | — | — |
MEL200, then MEL220 and Dexamethasone Variant #01 | — | R 997 | — | — | — | — | — | — |
Melphalan monotherapy, then Melphalan and TBI Variant #01 | — | R 807 | — | — | — | — | — | — |
Melphalan monotherapy, then TBI, then allo HSCT Variant #01 | — | R 475 | — | — | — | — | — | — |
Melphalan monotherapy Variant #01 | — | R 71 | 42d | 50.0 mo | — | 37 | R 2 636 PFS proxy | 4 |
Tandem melphalan Variant #03 | — | R 0 | — | 43.2 mo | — | — | — | 4 |
Lenalidomide and Prednisone (RP) N/A - secondary systemic drug | — | R 0 | 28d | ~37.5 mo | — | ~41 | ~R 0 PFS proxy · indirect | 1 |
Melphalan and TBI Variant #01 | — | R 0 | — | — | — | — | — | — |
TP Partial | — | — | — | — | — | — | — | — |
No consolidation Partial | — | — | — | — | — | — | — | — |
22 of 22 regimens shown